+ Reply to Thread
Page 4 of 100 FirstFirst ... 2 3 4 5 6 14 54 ... LastLast
Results 31 to 40 of 992

Thread: Sm04554

  1. #31
    Senior Member
    Join Date
    Jan 2012
    Posts
    795

    Default

    PHase I was just safety, they're unlikely to release efficacy data....if they even gave it enough time to work.

  2. #32
    Junior Member
    Join Date
    Oct 2014
    Posts
    17

    Default

    looks good

  3. #33
    Senior Member
    Join Date
    Sep 2014
    Posts
    101

    Default

    Quote Originally Posted by KO1 View Post
    PHase I was just safety, they're unlikely to release efficacy data....if they even gave it enough time to work.
    Anyone notice how they used a higher dosage during Phase I safety trials? Phase I used 0.05%, 0.15%, and 0.45%, while Phase II is using only 0.15% and 0.25%. Would there be safety issues regarding manipulating WNT pathways?

    The only other explanation is that they found 0.45% unnecessary and are narrowing down to the most efficient dosage.

    Doesn't this work similar to Histogen?

  4. #34
    Senior Member
    Join Date
    Dec 2012
    Posts
    226

    Default

    Quote Originally Posted by macbeth81 View Post
    Doesn't this work similar to Histogen?
    Kind of but not really. Histogen is growth factors which activate numerous pathways of which the WNT pathways is one of them. This drug merely activates the WNT pathway if I am correct. So different MoAs above all.

  5. #35
    Senior Member
    Join Date
    Jan 2012
    Posts
    795

    Default

    I think they just wanted to overdose just to check the tolerable range. But there are definitely safety issues with Wnt - it is an important signal in cancer growth.

  6. #36
    Senior Member
    Join Date
    Mar 2014
    Posts
    164

    Default

    regarding cancer, from my understanding is that wnt cause proliferation of cells and over expressed in caner cells which provide cancer the ability to spread and proliferate fast. in addition wnt is also required for certain type of carcinogenesis. the over proliferation of cells can lead to mutation that causes cancer. this is why wnt is effective in hair regeneration because it causes cells differentiation and proliferation.

  7. #37
    Senior Member
    Join Date
    Mar 2011
    Posts
    263

    Default

    Quote Originally Posted by macbeth81 View Post
    Anyone notice how they used a higher dosage during Phase I safety trials? Phase I used 0.05%, 0.15%, and 0.45%, while Phase II is using only 0.15% and 0.25%. Would there be safety issues regarding manipulating WNT pathways?

    The only other explanation is that they found 0.45% unnecessary and are narrowing down to the most efficient dosage.

    Doesn't this work similar to Histogen?
    Phase I trials are done to assess the safety of the treatment. They are done at doses higher than what would be administered in the final commercial product. You have to be able to define the toxicity, or lack there of, at the dosage levels intended to be used in the general public. The only way to do this is by exceeding the therapeutic dose and seeing if there is toxicity. If the safety profile is clean at a higher dose, they can proceed with future trials with little concern that lower doses would be toxic.

  8. #38
    Member
    Join Date
    Oct 2014
    Posts
    34

    Default

    Im wondering by wich mecanism this molecule works. What is the target ? We already have study on hair promoting effect for VPA as gsk3 inhibitor which then increase b catenin in nucleus (proteasome inhibitors also upregulate beta-catenin levels). We also have other good candidate for such purpose like 6-bio wich is a potent, reversible and ATP-competitive gsk3a/β inhibitor. This molecule is used in cell culture to maintain the properties of DP cells intact.

    Such molecules are by defintion anti cells proliferation activity so scientific use growth factor such as FGF2 in the media.

    There is a lot of question awaiting for an answer for this molecule. I would like more information about it

  9. #39
    Senior Member
    Join Date
    Jan 2012
    Posts
    795

    Default

    Quote Originally Posted by Shinobi View Post
    Im wondering by wich mecanism this molecule works. What is the target ? We already have study on hair promoting effect for VPA as gsk3 inhibitor which then increase b catenin in nucleus (proteasome inhibitors also upregulate beta-catenin levels). We also have other good candidate for such purpose like 6-bio wich is a potent, reversible and ATP-competitive gsk3a/β inhibitor. This molecule is used in cell culture to maintain the properties of DP cells intact.
    They have not released the mechanism by which it works, it might be a GSK-3b modulator, in which case I expect it to be more potent than VPA or 6BIO. This is a Pfizer molecule which the firm found in their chemical library and have the rights to.

    Quote Originally Posted by Shinobi View Post
    Such molecules are by defintion anti cells proliferation activity so scientific use growth factor such as FGF2 in the media.
    This is not correct, it will promote cell proliferation.

  10. #40
    Senior Member
    Join Date
    May 2014
    Posts
    803

    Default

    I hope we can get some more information about this trial, hopefully we will get updated through the 2nd trial so we will know the effectiveness. Somebody should sign up from the forum that would be awesome. I hope it will be more selective and better acting than something like VPA, that would be awesome.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts

» IAHRS

hair transplant surgeons

» The Bald Truth

» Recent Threads

Benefits of Resveratrol for hair and health
05-05-2022 01:46 AM
Last Post By felixten
Yesterday 11:59 PM
1800 graft repair case results by Dr. Lindsey
03-27-2024 08:38 AM
Last Post By Dr. Lindsey
03-27-2024 08:38 AM
Navigating the German Job Market as a Kenyan Citizen
11-04-2023 06:31 AM
Last Post By Keegan212
03-27-2024 03:51 AM